Last update Feb. 5, 2022

Tuaminoheptane Sulphate

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Volatile sympathomimetic with vasoconstrictor effect used as a nasal decongestant. It has hypertensive and tachycardial effects(Marsh 1951). Administration by intranasal spray.

At the date of the last update, there was no published data available on its excretion in human milk.

Product with very few and very old bibliographic references, marketed in few countries.

The virtual absence of pharmacokinetic data does not allow the prediction of its possible excretion in human milk.

Tuaminoheptane has been on the list of prohibited substances by the World Anti-Doping Agency since 2007. (Docherty 2008, Thevis 2007)

Urine levels are detected up to 2 to 4 days after intranasal administration. (Perrenoud 2009, Thevis 2007).

The isolated application, occasional, not continuous and without exceeding the prescribed dose could be compatible with breastfeeding.

Until more published data are known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

  • Acetylcysteine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Azelastine (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Budesonide inhaled ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Cetirizine Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Fluticasone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Loratadine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Oxymetazoline Hydrochloride (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tuaminoheptane Sulphate is also known as


Tuaminoheptane Sulphate in other languages or writings:

Group

Tuaminoheptane Sulphate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Tuaminoheptane Sulphate in its composition:

  • Rinofluimucil™. Contains other elements than Tuaminoheptane Sulphate in its composition

Pharmacokinetics

Variable Value Unit
Molecular weight 329 daltons

References

  1. Perrenoud L, Saugy M, Saudan C. Detection in urine of 4-methyl-2-hexaneamine, a doping agent. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3767-70. Abstract
  2. Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. 2008 Jun;154(3):606-22. Abstract
  3. Thevis M, Sigmund G, Koch A, Schänzer W. Determination of tuaminoheptane in doping control urine samples. Eur J Mass Spectrom (Chichester). 2007;13(3):213-21. Abstract
  4. MARSH DF, HERRING DA. The comparative pharmacology of the hydroxy and methyl derivatives of 6-methyl-2-heptylamine. J Pharmacol Exp Ther. 1951 Oct;103(2):178-86. No abstract available. Abstract

Total visits

4,253

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM